Boston Scientific Co. (NYSE:BSX) Shares Bought by Argent Trust Co

Argent Trust Co grew its stake in shares of Boston Scientific Co. (NYSE:BSX) by 4.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,500 shares of the medical equipment provider’s stock after purchasing an additional 753 shares during the quarter. Argent Trust Co’s holdings in Boston Scientific were worth $1,502,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Triad Wealth Partners LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $26,000. First Foundation Advisors acquired a new position in shares of Boston Scientific in the 1st quarter valued at $25,000. Eagle Bay Advisors LLC increased its holdings in shares of Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 309 shares during the period. Andra AP fonden acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $29,000. Finally, Lynx Investment Advisory acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BSX shares. The Goldman Sachs Group began coverage on shares of Boston Scientific in a report on Thursday, May 30th. They issued a “buy” rating and a $90.00 target price on the stock. Argus lifted their price objective on shares of Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, May 28th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research report on Thursday, July 25th. Barclays lifted their price objective on shares of Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. Finally, Robert W. Baird lifted their price objective on shares of Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $85.38.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 20,949 shares of company stock valued at $1,627,877. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Trading Up 0.1 %

NYSE BSX opened at $82.57 on Thursday. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $84.11. The company has a 50-day moving average of $78.46 and a 200-day moving average of $74.45. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14. The company has a market cap of $121.14 billion, a P/E ratio of 69.39, a P/E/G ratio of 2.75 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The company had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter in the prior year, the company posted $0.53 EPS. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, equities analysts predict that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.